Hand-foot syndrome following decitabine

Alaa M Ali; Meagan Jacoby; John S Welch

doi:10.1007/s00277-015-2546-1

Hand-foot syndrome following decitabine

Ann Hematol. 2016 Feb;95(3):535-6. doi: 10.1007/s00277-015-2546-1. Epub 2015 Nov 6.

Authors

Alaa M Ali¹, Meagan Jacoby², John S Welch³

Affiliations

¹ Division of Hospital Medicine, Washington University School of Medicine, St. Louis, USA.
² Division of Oncology, Stem Cell Biology Section, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8007, St. Louis, MO, 63110, USA.
³ Division of Oncology, Stem Cell Biology Section, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8007, St. Louis, MO, 63110, USA. jwelch@dom.wustl.edu.

Abstract

We observed a case of Hand-Foot Syndrome (HFS) in a patient treated with decitabine. HFS has not previously been associated with decitabine, although it has been observed following treatment with the structurally similar pyrimidine analogue cytarabine.

Publication types

Case Reports

MeSH terms

Antimetabolites, Antineoplastic / adverse effects*
Azacitidine / adverse effects
Azacitidine / analogs & derivatives*
Decitabine
Hand-Foot Syndrome / diagnosis*
Humans
Male
Middle Aged

Substances

Antimetabolites, Antineoplastic
Decitabine
Azacitidine

Grants and funding

R01 HL128447/HL/NHLBI NIH HHS/United States